- Services
- ABL1 Kinase Domain Mutation Analysis
- Chimerism Assessment by Polymorphic Microsatellite Markers
- Detection of BCR ABL Major Fusion Transcripts
- Detection of BCR ABL Minor Fusion Transcripts
- EndLeukemia RNA Translocation Assay Analysis
- FIP1L1-PDGFRA Fusion Transcript Detection
- FLT3 Mutational Analysis
- hMLH1 Methylation Status
- Immunoglobulin Heavy Chain Gene Rearrangement
- Inv(16)(p13.1q22);CBFB-MYH11 Fusion Transcript Detection
- JAK2 p.V617F Mutational Analysis
- EndLeukemia Assay
- MD EndLymphoma Mutation Analysis
- MD FLT3-ITD Follow up Mutation MRD Analysis
- MD Focused Pharamacogenomics Genotyping Assay
- MD HPV Liquid Biopsy
- MD NPM1 MRD Mutation Analysis
- MDA Mutation Analysis Precision Panel Liquid Biopsy
- MGMT Methylation Status
- Microsatellite Instability Analysis (Tumors)
- PML-RARA/t(15;17) Fusion Transcript Detection
- RUNX1-RUNX1T1/t(8;21)(q22;q22) Fusion Transcript Detection
- Somatic Hypermutation Analysis, IGH
- T cell Receptor Beta Gene Rearrangement
- T cell Receptor Gamma Gene Rearrangement
- TGFB1 Polymorphism Real-Time PCR Genotyping
Detection of BCR ABL Major Fusion Transcripts
Indication
The t(9;22)(q34;q11.2) translocation resulting in BCR::ABL1 fusion transcripts is seen in nearly all cases of chronic myelogenous leukemia (CML) and in a subset of acute lymphoblastic leukemia/lymphoma (ALL). This assay detects and quantifies e13a2 and e14a2 BCR::ABL1 transcripts (p210) arising from BCR breakpoints in the major breakpoint cluster region. The assay can be used for diagnosis, classification, post-treatment monitoring and minimal residual disease detection. The results are reported as the percentage international scale (%IS) for interlaboratory comparison of molecular milestones such as major molecular response (MMR). The test results must be interpreted in conjunction with clinical findings, hematologic data and other laboratory studies.
Methodology
Total RNA is extracted from the provided sample and reverse-transcribed into complementary DNA (cDNA). Quantitative real-time multiplex PCR amplification is performed using primers designed to t(9;22)(q34;q11.2)/BCR::ABL1 fusion transcripts in leukemia. Specifically, the assay is designed to detect e13a2 (b2a2) and e14a2(b3a2) involving the major breakpoint region. Standard curves for BCR::ABL1 and the ABL1 control are included in each assay to quantify the transcripts. A normalized copy number (NCN) is calculated for each sample as #BCR::ABL1 cDNA molecules/#ABL1 cDNA molecules. The NCN is then converted to a value on the international scale (IS) using a validated reference sample calibrated to a standard set of diagnostic specimens. The results are reported as percentage international scale (%IS).
Test Parameters
- Limit of detection: MR of 4.7 or %IS of 0.002%
- Limit of quantification (LOQ): MR of 4.7 or %IS of 0.002%
- Analytical measurement range: %IS of 0.002%–50%
Turnaround Time
Five to 10 working days
Sample Requirements
10–30 ml peripheral blood in lavender top (EDTA) tube, senton wet ice
or
2–5 ml of bone marrow aspirate in lavender top (EDTA) tube, sent on wet ice
CPT Codes
82106
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer who is being billed.
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.